ClinicalTrials.gg
RecruitingNCT05913414Updated Jun 22, 2023

Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma

A Phase 2 interventional study of Iron Isomaltoside 1000 and Polysaccharide Iron Complex Pill in Nasopharyngeal Carcinoma, Iron-deficiency and Anemia, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 186 studies in Nasopharyngeal Carcinoma by Sun Yat-sen University — 80 open to participants now, 107 under way, 43 of them phase 3. Nasopharyngeal Carcinoma · Sun Yat-sen University.

Planned enrollment
94th of 161
120 · median 162
Started
2023
with 13 others
Phase 2
72 of 186
30 open now
Primary completion
2024-05
later than 14 of 106 live
Registered
131st of 186
by date

Among the 186 studies in Nasopharyngeal Carcinoma by Sun Yat-sen University, this one is the 94th largest by planned enrollment of the 161 interventional ones that give a count, is one of 14 that started in 2023, is one of 72 in phase 2, reaches primary completion later than 14 of the 106 other live ones, and was the 131st registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

80 of the 186 studies in Nasopharyngeal Carcinoma by Sun Yat-sen University are open now, in 2 countries. Recruiting first, the newest first:

75 more — sign in →

By country, each count listing its studies:

All 80 open studies →

Where they have run

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Nasopharyngeal Carcinoma by Sun Yat-sen University, or all of them as a file.
02

Study summary

Primary purpose: To evaluate the difference of hematopoietic response rate at 1 month after concurrent chemoradiotherapy between iron isomaltide and oral iron supplement for treating iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma.

Secondary purpose:

To evaluate the difference of hematopoietic response rate, tolerance, acute side effects, qualtiy of life at 2 months and 3 months after concurrent chemoradiotherapy between Iron Isomaltide and oral iron supplement for treating iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma.

Read the detailed description

Iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma will be enrolled and receive iron Isomaltide or oral iron supplement after randomised. The hematopoietic response rate, tolerance, acute side effects, qualtiy of life and long time survival would be evaluated.

03

Conditions studied

  • Nasopharyngeal Carcinoma
  • Iron-deficiency
  • Anemia

Keywords

  • Nasopharyngeal Carcinoma
  • iron-deficiency anemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteer and sign the in person.
  • Aged 18-65
  • Pathological diagnosis of non-keratinizing NPC (differentiated or undifferentiated, as WHO II, III type).
  • Clinical stage of III-IVA(8thAJCC/UICC staging system)
  • Complete induction chemotherapy and concurrent chemoradiotherapy.
  • With score 0-1.
  • Female subjects: surgical sterilization or patients, or agree to use a medical approved measure such as Intrauterine device (IUD), contraceptives or condoms during the study period.
  • HGB \<130g/L(male),HGB\<120g/L(female).
  • Serum ferritin≤800ug/L。
  • Liver function: , AST \< 2.5 times the (ULN), total \< 2.0 × ULN;
  • Renal function: serum creatinine \<1.5×ULN.

Exclusion criteria

Exclusion Criteria:

  • Recurrence or distant nasopharyngeal carcinoma.
  • Keratinizing squamous cell carcinoma (WHO type I).
  • Pregnant or breastfeeding women, who are in their childbearing years and have not used effective .
  • Previous or concurrently with other , exclude cured skin basal cell carcinoma and cervical carcinoma in situ.
  • Patients with severely diminished functions of the heart, liver, lung, kidney and bone marrow;
  • Serious, unmanaged medical conditions and infections.
  • Those with other therapeutic .
  • Use of other medications or clinical studies concurrently.
  • Refused or incapacity to sign the to participate in the study.
  • People having mental or personality disorders, disability, or limited civil capacity.
  • Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study.
  • HGB>130g/L(male),HGB >120g/L(female).
  • Received transfusion therapy before.
  • Receipt of oral or IV iron supplements or ESAs up to 4 weeks before inclusion
  • Ferritin > 800 ng/ml
  • Ongoing bleeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Iron Isomaltide

    Patients receive iron Isomaltide after anti-tumor therapy.

    Drug: Iron Isomaltoside 1000 · Radiation: Intensity-modulated radiotherapy

  • Active comparator
    Oral iron supplement

    Patients receive polysaccharide iron complex after anti-tumor therapy.

    Drug: Polysaccharide Iron Complex Pill · Radiation: Intensity-modulated radiotherapy

Interventions

  • Patients receive Iron isomaltoside after IC and CCRT

    Also known as: Iron isomaltoside

  • DrugPolysaccharide Iron Complex Pill

    Patients receive Polysaccharide Iron Complex Pill after IC and CCRT

  • RadiationIntensity-modulated radiotherapy

    All patients received intensity-modulated radiotherapy before enrolled.

06

What researchers measure

Primary outcomes

  1. Hematopoietic response rate

    Hematopoietic response rate at one month after IC+CCRT.

    Time frame: 1 month

Secondary outcomes

  1. Hematopoietic response rate

    Hematopoietic response rate at two months after IC+CCRT.

    Time frame: 2 month

  2. Hematopoietic response rate

    Hematopoietic response rate at three months after IC+CCRT.

    Time frame: 3 month

  3. Acute side effects

    The acute side effects of iron isomaltide

    Time frame: 1 month

  4. Quality of life scores

    The scores of each scale of quality of life questionaires for FACT-An

    Time frame: 1 month

  5. The difference of HGB

    The difference of HGB after patients receiving iron supplements

    Time frame: 1,2,3 months

  6. The score of concise fatigue scale

    Calculated by Concise fatigue scale

    Time frame: 1,2,3 months

  7. The difference of serum iron

    The difference of HGB after patients receiving iron supplements

    Time frame: 1,2,3 months

07

Study locations

1 of 1 sites recruiting
  • Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Haiqiang Mai, MD,Ph.D · Contactmaihq@mail.sysu.edu.cn · 86-20-8734-3643
    • Qiuyan Chen, MD,Ph.D · Contactchenqy@mail.sysu.edu.cn · 86-20-8734-3380
    • Haiqiang Mai, MD,Ph.D · Principal investigator
    • Qiuyan Chen, MD,Ph.D · Principal investigator
    • Shanshan Guo, MD,Ph.D · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2024, 12 months after the start.

Of 128 non-industry phase 2 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's planned 12 months is below that.

Counting every sponsor, half of 143 studies reached it within 43 months; a quarter within 28 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2023
First posted
Jun 22, 2023
StartActual
May 5, 2023
Primary completionEst.
May 30, 2024
CompletionEst.
May 30, 2026
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05913414
Responsible party
Hai-Qiang Mai,MD,PhD (Professor, Sun Yat-sen University) — Principal investigator
First posted
Jun 22, 2023
Start date
May 5, 2023
Primary completion
May 30, 2024 (estimated)
Completion
May 30, 2026 (estimated)
Last update
Jun 22, 2023

Study contacts

Qiu Yan Chen, Dr
Contact
chenqy@sysucc.org.cn
020-87343380
Shan Shan Guo, Dr
Contact
guoshsh@sysucc.org.cn
020-87343380
Shan Shan Guo, Dr
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion